Old drug, new hope: enasidenib may ease anemia in certain blood cancers
NCT ID NCT05282459
First seen Apr 20, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early-phase study tested the drug enasidenib in 17 adults with lower-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML) who did not have a specific gene mutation (IDH2). The goal was to see if the drug could safely improve anemia and reduce the need for blood transfusions. Researchers also looked at how the drug affects red blood cell production.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.